cPLA2alpha inhibitor ASB14780 suppresses airway MMP-9 production and improves respiratory function in cigarette-smoke induced model Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014
Dual inhibition of thromboxane synthase and 5-lipoxygenase, potentially significant mechanism for the treatment of asthma Source: Eur Respir J 2001; 18: Suppl. 33, 264s Year: 2001
Elevated IL-10 level but not cysteinyl leukotrienes (CysLT) release from leukocytes in vitro correlates with good response to treatment with montelukast in asthmatic patients Source: International Congress 2014 – Asthma and COPD management Year: 2014
Over-expression of the LTC4 synthase gene in mice reproduces human aspirin-induced asthma (AIA) Source: Annual Congress 2013 –Genetics and mechanisms of, and tests for, allergy Year: 2013
No shunting towards LTB4 when blocking LTC4s in vitro Source: International Congress 2015 – Therapeutic approaches in inflammatory lung disease Year: 2015
Quantitative assessment of cysteinyl leukotrienes in human sputum during the allergen-induced asthmatic response and the effect of GSK2190915, a 5-lipoxygenase activating protein (FLAP) inhibitor Source: Annual Congress 2011 - Diagnosis and treatment of inflammatory respiratory diseases Year: 2011
Evidence of mast cell activation and leukotriene release after mannitol inhalation Source: Eur Respir J 2003; 22: 491-496 Year: 2003
In vitro pharmacological characterization of CHF6001, a novel selective phosphodiesterase 4 (PDE4) inhibitor with a robust anti-inflammatory profile Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014
Imbalance of anti-inflammatory (lipoxin A4) and pro-inflammatory (leukotrien B4) arachidonic acid products in exhaled breath condensate of severe refractory asthma. Source: International Congress 2014 – Airway biomarkers Year: 2014
Inhibition of eosinophil migration by montelukast, a cysteinyl leukotriene receptor antagonist, through down regulation of plasmin activity Source: Eur Respir J 2004; 24: Suppl. 48, 36s Year: 2004
Inhibition of mast cell PGD2 release protects against mannitol-induced airway narrowing Source: Eur Respir J 2006; 27: 944-950 Year: 2006
Interactive inhibitory effects of formoterol and montelukast on activated human neutrophils Source: Eur Respir J 2010; 36: 1417-1424 Year: 2010
Inhibition of phosphodiesterase 4B enhances glucocorticoid-dependent gene transcription in human airway epithelial cells: Implications for the treatment of COPD Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013
CHI-91040, a novel inhaled p38α inhibitor, counteracts lung inflammation induced by IL-1β in the rat Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016
Anti-inflammatory effects of the novel phosphodiesterase type 4 inhibitor CHF6001 on COPD alveolar macrophages and lung tissue Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014
Therapeutic blockade of IL-4 and 13 signaling with dupilumab (SAR231893/REGN668) inhibits key biomarkers in asthma Source: Annual Congress 2013 –Treatment of asthma Year: 2013
Oral administration of a new prostacyclin agonist with thromboxane synthase inhibitory activity improves bleomycin-induced lung fibrosis Source: Annual Congress 2010 - New insights in the treatment of idiopathic pulmonary fibrosis Year: 2010
Stimulation of IL-8 release in respiratory cell cultures by increasing IL1-beta concentrations: Effect of budesonide Source: Annual Congress 2013 –Asthma: new mechanisms and markers Year: 2013
The polyamine spermine inhibits mitochondrial permeability transition (mPT) and apoptosis in human eosinophils Source: International Congress 2014 – Cell biology 2014 Year: 2014
Effects of zileuton on leukotriene formation in human blood cells and expression of enzymes in the biosynthetic pathway Source: Eur Respir J 2006; 28: Suppl. 50, 316s Year: 2006